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Lipids play an important role as risk or protective factors in Alzheimer’s disease (AD). Previously it has been shown that
plasmalogens, the major brain phospholipids, are altered in AD. However, it remained unclear whether plasmalogens themselves
are able to modulate amyloid precursor protein (APP) processing or if the reduced plasmalogen level is a consequence of AD.
Here we identify the plasmalogens which are altered in human AD postmortem brains and investigate their impact on APP
processing resulting in Aβ production. All tested plasmalogen species showed a reduction in γ-secretase activity whereas β-a n d
α-secretase activity mainly remained unchanged. Plasmalogens directly aﬀected γ-secretase activity, protein and RNA level of
the secretases were unaﬀected, pointing towards a direct inﬂuence of plasmalogens on γ-secretase activity. Plasmalogens were
also able to decrease γ-secretase activity in human postmortem AD brains emphasizing the impact of plasmalogens in AD. In
summary our ﬁndings show that decreased plasmalogen levels are not only a consequence of AD but that plasmalogens also
decrease APP processing by directly aﬀecting γ-secretase activity, resulting in a vicious cycle: Aβ reduces plasmalogen levels and
reduced plasmalogen levels directly increase γ-secretase activity leading to an even stronger production of Aβ peptides.
1.Introduction
Plasmalogens are glycerophospholipids and major constit-
uents of neuronal membranes. Beside human brain, where
plasmalogens represent almost 20%oftotalglycerophospho-
lipids, they can be found in all mammalian tissues, especially
in the heart muscle [1–3]. Characteristic of plasmalogens is
an enol etherdoublebondat the sn-1 position of theglycerol
backbone (Figure 1), which makes plasmalogens more sus-
ceptible to oxidative stress than the corresponding ester-
bonded glycerophospholipid, thus protecting cells from oxi-
dative stress [4]. Beside their function as antioxidants, plas-
malogens are involved in membrane fusion [5, 6], ion trans-
port [7–9], and cholesterol eﬄux [10, 11]. Furthermore,
plasmalogens can be hydrolyzed by plasmalogen-selective
phospholipase A2 [3, 12], generating fatty acids like arachi-
donic acid, which is important for modulating ion channels,
regulating diﬀerent enzyme activities like protein kinase A,
protein kinase C, NADPH oxidase, Na+K+-ATPase, and oth-
ers [13]. Arachidonic acid released from plasmalogens can
be metabolized to eicosanoids, acting as second messengers
[14]. Due to the fact that plasmalogens represent major con-
stituents of neuronal membranes and are involved in dif-
ferent cellular processes, it is not unexpected that neuronal
function also dependson a delicatebalance in lipidcomposi-
tion ofcellularmembranes. Alterationsofplasmalogen levels
occurin severalneurologicaldisordersincludingAlzheimer’s
disease (AD) [15–17], spinal cord trauma [18], ischemia
[19, 20], Niemann-Pick disease [21], and multiple sclerosis
[22]. For AD, plasmalogen levels have been described to be2 The Scientiﬁc World Journal
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Figure 1: Structure of plasmalogen (PL) and the corresponding phospholipid used in this study. In the plasmalogens, the fatty acid is
linked via an enol ether bond instead of an ester bond marked in red. Residue 1 (R1) can either be a phosphatidylcholine or a phos-
phatidylethanolamine leading to PC-plasmalogen or PE-plasmalogen. The sn-2 position can vary in diﬀerent fatty acids symbolized by
residue 2 (R2).
reduced in autopsy brain samples from AD patients com-
pared to age-matched control brains [15–17, 23, 24]. How-
ever, Pettegrew et al. reported no diﬀerences or even a
slight increase in AD patients [25]. One of the characteristic
pathological hallmarks of AD is the massive accumulation
of a small peptide, called amyloid beta peptide (Aβ)t h a t
aggregates in amyloid plaques [26, 27]. Aβ is generated
by sequential processing of the amyloid precursor protein
(APP), a type I integral membrane protein [28]. For the
generation of Aβ,A P Pi sﬁ r s tc l e a v e db yβ-secretase BACE1,
a membrane-bound aspartyl-protease [29], generating β-
secreted APP (sAPPβ), and a C-terminal membrane-bound
fragment, called C99 or β-CTF. C99 is further processed by
γ-secretase, releasing the Aβ peptide. The γ-secretase has
been identiﬁed as a multimeric complex of at least four
transmembrane proteins, presenilin 1 (PS1) or presenilin
2 (PS2), nicastrin, anterior pharynx-defective 1 (Aph-1),
and presenilin enhancer 2 (Pen-2) [30]. The polytopic
transmembrane proteins PS1 or PS2 constitutethe active site
of the protease [31]. Beside the amyloidogenic processing of
APPinvolving β-a n dγ-secretase activity, APPcanbecleaved
in a nonamyloidogenic pathway by α-secretases [32, 33]. The
α-secretases have been identiﬁed as members of the ADAM
family (a disintegrin and metalloproteinase), cleaving APP
withintheAβdomainand therefore preventthe formation of
Aβ [33–35]. As APP and its processing secretases are all inte-
gral membrane proteins, we analyzed in this study whether
plasmalogens, major components of neuronal membranes,
inﬂuence amyloidogenic and nonamyloidogenic processing
of APP.
2.Materialsand Methods
2.1. Chemicals and Reagents. All phosphatidylcholine and
phosphatidylethanolamine species used in this study were
purchased from Avanti Polar Lipids (Alabaster, AL, USA).
Bovine serumalbuminwaspurchased fromRoth(Karlsruhe,
Germany). All other reagents if not otherwise stated were
purchased from Sigma Aldrich (Taufkirchen, Germany).
2.2. Cell Culture. SH-SY5Y cells were cultivated in Dul-
becco’s Modiﬁed Eagle’s Medium (Sigma, Taufkirchen, Ger-
many) with 10% FCS (PAN Biotech, Aidenbach, Germany).
For incubation phospholipids solved in ethanol p.a. (Sigma,
Taufkirchen, Germany) were added in a ﬁnal concentration
of 100μM to culture media with 0.1% FCS. Incubation
was carried out for 24h with changing incubation medium
with phospholipids after 12h. Lactate Dehydrogenase-assay
analysisrevealednosignsforelevatedcytotoxicityorreduced
membrane integrity in presence of phospholipids (which is
available at doi:10.1100/2012/141240).
2.3. Brain Samples. In total, 58 human postmortem brain
samples from 21 control and 37 Alzheimer’s disease patients
were used. For more details, see Table 1.F u r t h e r m o r e ,f o r
ex vivo analysis of γ-secretase activity postnuclear fractions
from further 6 human postmortem brains obtained from
conﬁrmed AD patients were utilized. All human postmortem
brains were obtained from BrainNet (Munich, Germany).
In addition, postnuclear fractions from C57BI6/N wild-
type mice were used. Preparation of postnuclear fractions is
described in detail below.
2.4. Protein Amount Determination. All samples, including
human postmortem brains and cells, were homogenized on
ice using a PotterS (Braun, Melsungen, Germany) at 1500
revolutions per minute and 50 strokes. Protein determina-
tion was carried out according to Smith et al. [37]. Brieﬂy,
20μL of bovine serum albumin in a concentration range of
0.1–1.2μg/μL were used for determination of the standard
curve. For determination of samples’ protein amount, 1-
2μL of each sample was loaded in triplicate onto a 96 wellThe Scientiﬁc World Journal 3
Table 1: List of all human brains (n = 58) used for analysis.Human brain samples were kindly provided from BrainNet (Munich). In total,
we used 58 human brain samples from 21 control and 37 AD patients. Brains were obtained from patients with an age at death between
61 and 88 years, and no signiﬁcant diﬀerences in age and gender were observed between control (mean 75 years) and AD patients (mean
78 years) group. Abbreviations used are AD = Alzheimer’s disease; F = female; M = male; CERAD = the consortium to establish a registry
for AD, standardizing procedures for the evaluation and diagnosis if patients with AD. A, B, C, 0 as described in http://cerad.mc.duke.edu/;
Braak and Braak = Braak and Braak stage of AD; H. Braak and E. Braak stages [36]; FR = frontal cortex; n.d. = not determined.
# Age at death Sex Diagnosis Postmortem delay [h] Braak and Braak CERAD Brain region
Con #01 69 n.d. Control 14 n.d. n.d. n.d.
Con #02 77 F Control n.d. II A FR
Con #03 61 M Control 24 0 0 FR
Con #04 85 F Control 20 I 0 FR
Con #05 80 F Control n.d. III-IV 0 FR
Con #06 75 M Control 27 II 0 FR
Con #07 71 M Control 23 0-I 0 FR
Con #08 79 n.d. Control 20 n.d. n.d. n.d.
Con #09 62 n.d. Control 48 n.d. n.d. n.d.
Con #10 88 F Control 48 I-II B FR
Con #11 64 n.d. Control 15 n.d. n.d. n.d.
Con #12 69 n.d. Control 30 n.d. n.d. n.d.
Con #13 83 F Control 22 II 0 FR
Con #14 74 n.d. Control 23 n.d. n.d. n.d.
Con #15 85 M Control 25 III-IV B FR
Con #16 76 F Control 26 III-IV C FR
Con #17 87 M Control 48 I-II 0 FR
Con #18 71 n.d. Control 48 n.d. n.d. n.d.
Con #19 75 F Control 24 III-IV B FR
Con #20 77 F Control 20 II C FR
Con #21 63 M Control 18 I 0 FR
AD #01 83 M AD 22 VI C FR
AD #02 78 F AD 21 VI C FR
AD #03 76 M AD 14 V B FR
AD #04 88 F AD 39 VI C FR
AD #05 67 F AD 49 V-VI C FR
AD #06 82 F AD 33 V C FR
AD #07 80 M AD 12 V C FR
AD #08 75 M AD 24 VI C FR
AD #09 74 M AD 50 V-VI C FR
AD #10 83 M AD 37,5 VI C FR
AD #11 80 M AD 13 V C FR
AD #12 88 F AD 36 V C FR
AD #13 73 M AD 24 V-VI C FR
AD #14 62 M AD n.d. VI C FR
AD #15 70 M AD 39 VI C FR
AD #16 81 n.d. AD n.d. n.d. n.d. FR
AD #17 75 F AD 12 VI C FR
AD #18 73 n.d. AD n.d. n.d. n.d. FR
AD #19 78 F AD n.d. V-VI C FR
AD #20 79 n.d. AD 18 >VC F R
AD #21 86 n.d. AD 42 >VC n . d .
AD #22 85 F AD n.d. IV C FR
AD #23 75 n.d. AD 18 VI C n.d.
AD #24 80 F AD 48 V C FR
AD #25 73 F AD n.d. V-VI C FR
AD #26 85 F AD n.d. III C FR4 The Scientiﬁc World Journal
Table 1: Continued.
# Age at death Sex Diagnosis Postmortem delay [h] Braak and Braak CERAD Brain region
AD #27 80 n.d. AD 5 >VC n . d .
AD #28 78 F AD n.d. VI C FR
AD #29 87 M AD 4 V C FR
AD #30 65 F AD 48 V-VI C FR
AD #31 82 F AD 14 V-VI C FR
AD #32 76 F AD 24 V-VI C FR
AD #33 79 F AD 20 V C n.d.
AD #34 87 M AD 26 V C FR
AD #35 68 F AD n.d. VI C FR
AD #36 85 n.d. AD n.d. n.d. n.d. FR
AD #37 83 M AD 48 V C FR
plate (Nunc, Langenselbold, Germany). 200μLo fr e a g e n t
buﬀer (CuSO4:bicinchoninic acid; 1:39; Sigma Aldrich,
Taufkirchen, Germany) wasaddedtoeachwell using amulti-
channel pipette (Eppendorf, Hamburg, Germany). Incuba-
tion took place for 15 minutes at 37◦C and afterwards for
further 15 minutes at room temperature while shaking (IKA,
Staufen, Germany) at 300 revolutions per minute. Absorb-
ance was measured at a wavelength of 560nm using a Multi-
scanEX (Thermo Fisher Scientiﬁc, Schwerte, Germany).
2.5. Western Blot Analysis. For detection of ADAM17, PS1
and BACE1 protein amount, proteins of cell lysate were sep-
arated on 10%–20% Tricine gels (Anamed, Groß-Bieberau,
Germany). Western Blot (WB) analysis was performed using
antibody ab39162 (1:5000; abcam, Cambridge, UK), sc-
7860 (1:500; Santa Cruz, Heidelberg, Germany), and B0806
(1:1000;Sigma,Taufkirchen, Germany)respectively.W401B
(1:10000; Promega, Mannheim, Germany) was used as sec-
ondary antibody, and detection was carried out using West-
ern Lightning Plus-ECL solution (Perkin Elmer, Rodgau,
Germany). Densiometric quantiﬁcation was performed us-
ing Image Gauge software.
2.6. Postnuclear Fractions. For preparing postnuclear frac-
tions (PNFs) SH-SY5Y wild-type cells, mouse brains or
human AD brains were washed with PBS and homogenized
in sucrose-buﬀer (pH 7.4) using a PotterS (Braun, Melsun-
gen, Germany) at maximum speed. Protein amount was
adjusted to 2mg/mL for β-a n dγ-secretase assay and to
1mg/mLformeasuringα-secretase activity.Aftercentrifuga-
tion at 900rcf for 10min at 4◦C supernatants were collected
and stored at −80◦C.
2.7. In Vitro Incubation. PNFs were warmed up at 37◦C,
and phospholipids solved in ethanol p.a. were added in a
ﬁnal concentrationof 100μM. Sampleswere incubated while
shaking (Multireax, Heidolph Instruments, Schwabach, Ger-
many) for 15min at 37◦C before being centrifuged at
55.000rpm for 75min at 4◦C for pelleting membranes.
2.8. Secretase Activities
α-Secretase Activity. Pelleted SH-SY5Y membranes were re-
suspended in 1mL, and puriﬁed mouse brain membranes
were resuspended in 2mL Hepes-buﬀer pH 7.5. Forsolubili-
sation, samples were passed through needles (BD, Franklin
Lakes, NJ, USA) with decreasing diameters. Samples were
dispended in triplicate onto a black 96-well plate using
100μL per well corresponding to 100μgf o rS H - S Y 5 Ya n d
50μg for mouse brain membranes. After adding 3μM α-
secretase-substrate (Calbiochem, Darmstadt, Germany), ﬂu-
orescence was detected with excitation wavelength at 340 ±
10nm and emission wavelength at 490 ± 10nm using Saﬁre
2
Fluorometer (Tecan, Crailsheim, Germany). Kinetic was
plottedfor120cycleswith kineticintervalsof120s. Forspec-
iﬁcity control, 10mM EDTA/EGTA was used (supplement
Figure S2).
β-a n dγ-Secretase Activities. Pelleted membranes were re-
suspendedin800μLsucrose-buﬀerforSH-SY5Ymembranes
and 400μL for mouse brain and human AD brain mem-
branes. Membranes were solubilized as described above.
For analysing γ-secretase activity, samples were dispensed
in triplicate on black 96-well plates (Corning, Lowell, MA,
USA) using 100μL per well corresponding to 250μgf o r
SH-SY5Y membranes and 500μg for mouse and human
brain membranes. After adding 10μM γ-secretase sub-
strate (Calbiochem, Darmstadt, Germany), ﬂuorescence was
measured with excitation wavelength 355 ± 10nm and
ﬂuorescence detection at 440 ± 10nm in a Saﬁre2 Fluo-
rometer (Tecan, Crailsheim, Germany) at 37◦Cu n d e rl i g h t
exclusion. Kinetics were plotted for 50 cycles with kinetic
intervals of 180s. For determination of assay speciﬁcity, we
used γ-secretase Inhibitor X (50μM) (Calbiochem, Darm-
stadt, Germany) (supplement Figure S3). For measuring
β-secretase activity, samples were dispensed in triplicate
on black 96 well plates (50μL per well corresponding to
125μg for SH-SY5Y membranes and 250μgf o rm o u s eb r a i n
membranes). β-secretase substrate (Calbiochem,Darmstadt,
Germany) was added with a ﬁnal concentration of 20μMThe Scientiﬁc World Journal 5
and ﬂuorescence was detected with an excitation wave-
length at 345 ± 5nm and emission wavelength at 500 ±
2.5nm under light exclusion at 37◦C. Kinetics were plotted
for 180 cycles with kinetic intervals of 60s. Assay speciﬁcity
was validated using β-secretase Inhibitor II (1μM) (Cal-
biochem,Darmstadt,Germany) (supplementFigureS4).For
all secretase assays, the unspeciﬁcity was between 10% to
30%. The secretase activities presented, were calculated by
subtracting the unspeciﬁc turnover determined by adding
secretase inhibitors.
2.9. Mass Spectrometry Analysis. For determination of phos-
phatidylcholine and phosphatidylethanolamine levels in
human control and AD brains, we used a 4000 quadrupole
linear-ion trap (QTrap) equipped with a Turbo-V ion source
(AB SCIEX, Darmstadt, Germany) connected to a 1200 Agi-
lent HPLC (Agilent, B¨ oblingen, Germany). Brieﬂy, samples
were adjusted to 6mg/mL protein amount and 10μLo ft h e
adjusted samples was pipetted onto a membrane (Whatman,
GE Healthcare, Freiburg, Germany) ﬁxed in the wells of a
MultiScreen, solvinert 96-well plate with a 0.45μms t e r i l e
ﬁlter at the bottom (Millipore, Schwalbach, Germany). This
96 well plate was placed onto a 1mL 96-well deep well
plate (Nunc, Langenselbold, Germany). Samples were dried
under a gentle ﬂow of nitrogen for at least 30min at room
temperature. Meanwhile, phenylisothiocyanate was diluted
in ethanol:water:pyridine (1:1:1; v/v/v) to obtain a ﬁnal
5% phenylisothiocyanate solution. 20μL of this solution
was pipetted onto each membrane, and the plate was
incubated for 20min at room temperature and afterwards
dried under a gentle ﬂow of nitrogen for at least 30min.
Samples were extracted using 300μL 5mM ammonium
acetate buﬀer in methanol using a multichannel pipette
(Eppendorf, Germany) and the plate was shaken at 300
revolutions per minute using a plate shaker (IKA, Staufen,
Germany) at room temperature for 30min. Samples were
centrifuged (Thermo Scientiﬁc, Langenselbold, Germany)
at 500×g for 2min through 0.45μm sterile ﬁlters into
the 96 deep well plate and further diluted with 600μLo f
5mM ammonium acetate dissolved in methanol:water
(97:3, v/v) which also was used as the only running solvent.
Finally plate was covered with a silicone mat and shook for
further 2min at 300rpm at room temperature. Plate was
placedintothecooledautosampleranddetectionwascarried
out using Analyst 1.5 software (AB SCIEX, Darmstadt,
Germany). Phosphatidylcholine species were detected
using MRM transitions (PCae C34:1: 746,6m/z − 184m/z;
PCae C36:4: 768,6m/z − 184m/z; PCae C36:2: 772,6m/z
− 184m/z; PCae C36:1: 774,6m/z − 184m/z; PCae C38:6:
792,6m/z − 184m/z; PCae C38:5: 794,6m/z − 184m/z;
PCae C38:4: 796,6m/z − 184m/z; PCae C40:6: 820,6m/z
− 184m/z), and phosphatidylethanolamine species were
detected using a neutral loss scan for 141m/z (PEae 36:4:
728,8m/z; PEae 36:2: 732,8m/z; PEae 38:6: 752,8m/z;
PEae 38:5: 754,8m/z; PEae 38:4: 756,8m/z; PEae 40:6:
780,8m/z). For both species detection, 20μL sample was
injected into sample loop with the following running solvent
gradient (0.0–2.4min, 30μL; 2.4–3.0min, 200μL; 3.0min,
30μL).
2.10. Quantitative Real-Time Experiments. RNAwas extract-
ed in total from cells using TRIzol reagent (Invitrogen, Karl-
sruhe, Germany), according to manufacturer’s protocols.
High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Darmstadt, Germany) was used to reverse-
transcribe 2μg total RNA. Quantitative real-time PCR anal-
ysis was carried out using Fast SYBR Green Master Mix on
7500 Fast Real-Time PCR System (7500 Fast System SDS
Software 1.3.1.; Applied Biosystems, Darmstadt, Germany).
All results were normalized to β-actin gene expression and
changes detected in gene expression were calculated using
2−(ΔΔCt) method [38]. The following primer sequences were
used: ADAM17: 5 -CTG TGT GCC CTA TGT CGA TG-3 
and 5 -CAG CTG GTC AAT GAA ATC CC-3 ; BACE1: 5 -
GCA GGG CTA CTA CGT GGA GA-3  and 5 -TAG TAG
CGA TGCAGGAAGGG-3 ;PSEN1:5 -CTCAATTCTGAA
TGC TGC CA-3  and 5 -GGC ATG GAT GAC CTT ATA
GCA-3 ; PSEN2: 5 -GAT CAG CGT CAT CGT GGT TA-3 
and 5 -GGA ACA GCA GCA TCA GTG AA-3 ; APH1a: 5 -
CAGCCATTA TCCTGCTCCAT-3  and5 -GGA ATG TCA
GTCCCGATGTC-3 ;APH1b:5 -GTGTCAGCCCAGACC
TTC AT-3  and 5 -CAG GCA GAG TTT CAG GCT TC-3 ;
NCSTN:5  -CTG TAC GGA ACC AGG TGG AG-3  and 5 -
GAG AGG CTG GGA CTG ATT TG-3 ; PSENEN: 5 -CAT
CTT CTGGTT CTTCCGAGAG-3  and 5 -AGA AGA GGA
AGC CCA CAG C-3 ; β-Actin: 5 -CTT CCT GGG CAT GGA
GTC-3  and 5 -AGC ACT GTG TTG GCG TAC AG-3 .T o
verify the results obtained by quantitative real time experi-
ments, samples were separated on 3% agarose gels in TBE
buﬀer(90mM Tris, 90mM boric acid, 2mM EDTA, pH8.0).
2.11. Cytotoxicity Measurement. Cytotoxicity was measured
utilizing Lactate Dehydrogenase CytotoxicityAssay Kit (Cay-
man Chemical, Ann Arbor, USA) according to manufac-
turer’s protocol.
2.12. Statistical Analysis. All quantiﬁed data presented here
is based on an average of at least three independent experi-
ments. Error bars represent standard deviation of the mean.
Statistical signiﬁcance was determined by two-tailed Stu-
dent’s t-test; signiﬁcance was set at ∗P ≤ 0.05; ∗∗P ≤ 0.01
and ∗∗∗P ≤ 0.001.
3.Results
3.1. Determination of PC-PL and PE-PL Levels in Human
AD Postmortem Brain. In our previous studies, we reported
a decrease in total phosphatidylethanolamine-plasmalogen
(PE-PL) [39] and some phosphatidylcholine-plasmalogen
(PC-PL) species [40]i npostmortem AD brains. To elucidate
the question which plasmalogen species are mostly changed
in AD,we determined in thisstudy themajor PE-PL and PC-
PL species. In total, we analyzed 58 human brain samples, 21
control brains with an average age of 75 years, and 37 brain
samples obtained from ADpatients with an averageage of 78
years (Table 1). There were no signiﬁcant diﬀerences in the
age and sex of AD patients and controls. Mass spectrometry
analysis revealed thatPC-PL levelswere signiﬁcantly reduced6 The Scientiﬁc World Journal
Table 2: Analyzed PC-PL and PE-PL species in human AD postmortem brains compared to healthy individuals. Levels of all analyzed PC-
PL and PE-PL species were reduced in human AD postmortem brains. Statistical signiﬁcance was determined by two-tailed Students t-test.
SEM = standard deviation of the mean.
Metabolite % (compared to control) SEM t-test
PC-PL 16:0/18:1 (PC-PL 34:1) 64,55 1,654 0,0011
PC-PL 18:0/18:1 (PC-PL 36:1) 68,93 1,814 0,0005
PC-PL 18:1/18:1 (PC-PL 36:2) 49,17 1,452 0,0007
PC-PL 16:0/20:4 (PC-PL 36:4) 81,56 2,681 0,0483
PC-PL 18:0/20:4 (PC-PL 38:4) 85,02 1,930 0,0051
PC-PL 18:1/20:4 (PC-PL 38:5) 84,58 3,744 0,1105
PC-PL 16:0/22:6 (PC-PL 38:6) 88,21 2,925 0,0735
PC-PL 18:0/22:6 (PC-PL 40:6) 88,99 2,388 0,0184
PE-PL 18:1/18:1 (PE-PL 36:2) 83,18 7,252 0,2152
PE-PL 16:0/20:4 (PE-PL 36:4) 78,67 7,181 0,1631
PE-PL 18:0/20:4 (PE-PL 38:4) 80,55 6,795 0,1540
PE-PL 18:1/20:4 (PE-PL 38:5) 93,96 6,194 0,5656
PE-PL 16:0/22:6 (PE-PL 38:6) 94,07 6,250 0,5752
PE-PL 18:0/22:6 (PE-PL 40:6) 86,24 5,190 0,2049
Table 3: RT-PCR analysis of α-secretase ADAM17, the γ-secretase components and β-secretase BACE1 in presence of PC-PL 18:1 and PC-
PL 20:4 compared to the corresponding phospholipids PC 18:1 and PC 20:4 as control. The abbreviations set are ADAM17 = α-secretase,
PSEN1 = presenilin1, PSEN2 = presenilin2, APH1a = anterior pharynx-defective 1a, APH1b = anterior pharynx-defective 1b, NCSTN =
nicastrin, PSENEN2 = presenilin enhancer 2, and SEM = standard deviation of the mean. Statistical signiﬁcance was determined by two-
tailed Student’s t-test.
Gene % (compared to control) SEM t-test
PC-PL 18:0/18:1
α-secretase ADAM17 110,65 17,775 0,5658
γ-secretase
PSEN1 96,32 11,721 0,7574
PSEN2 103,59 13,585 0,7981
APH1a 87,01 23,043 0,5884
APH1b 106,43 18,578 0,7380
NCSTN 87,42 20,414 0,5548
PSENEN2 108,75 14,912 0,5734
β-secretase BACE1 104,24 22,534 0,8554
PC-PL 18:0/20:4
α-secretase ADAM17 90,44 4,919 0,0878
γ-secretase
PSEN1 94,97 9,865 0,6162
PSEN2 110,28 10,516 0,3568
APH1a 86,45 8,927 0,1676
APH1b 92,58 12,544 0,5707
NCSTN 85,93 8,304 0,1287
PSENEN2 98,99 7,433 0,8949
β-secretase BACE1 92,90 9,413 0,4607
in AD postmortem brains compared to healthy individuals,
whereasPC-PL18:1/18:1showedthestrongestreductionto
49,17% (Table 2). PE-PL levels were also reduced; however,
changes in individual species were not signiﬁcant (Table 2).
However, the question whether a reduced plasmalogen level
is caused by AD or plasmalogens themselves aﬀect AD by
directly aﬀecting APP processing remained unclear and is
addressed by the following experiments. As PC-PL 18:1
showed the strongest reduction in ADpostmortem brains, we
mainly focused on this lipid species and veriﬁed our results
with PC-PL 20:4, PC-PL 22:6 or PE-PL 22:6.
3.2. Plasmalogens Do Not Aﬀect Gene Expression of α-, β-, and
γ-Secretase. In order to analyze whether plasmalogens aﬀect
APPcleavagebymodulatinggeneexpression ofthesecretases
involved in the nonamyloidogenic and amyloidogenic pro-
cessing of APP, we performed RT-PCR analysis of ADAM17,
BACE1, and the components of the γ-secretase complex,
PS1, PS2, Aph1a, Aph1b, nicastrin, and Pen-2 (Table 3).
Therefore, cultured cells were incubated with the plasmalo-
gens PC-PL 18:1 and PC-PL 20:4, respectively. Control
cells were incubated with the corresponding phospholipid.
As cellular system, we used the human neuroblastoma cellThe Scientiﬁc World Journal 7
line SH-SY5Y. Signiﬁcant changes in gene expression of
ADAM17, BACE1, and the γ-secretase components were
not observed, neither for PC-PL 18:1 nor for PC-PL 20:4
(Table 3). In accordance, total protein level of ADAM17, PS1
and BACE1 were not aﬀected in presence of PC-PL 18:1 or
PC-PL 20:4 (Figures 2(a) and 2(b)).
3.3. Inﬂuence of Plasmalogens on β-Secretase Activity. Cleav-
age of APP by β-secretase BACE1 is the initial step in the
amyloidogenic processing of APP and the generation of Aβ
peptides. To examine whether plasmalogens inﬂuence β-
secretase activity directly, we ﬁrst prepared puriﬁed mem-
branes of SH-SY5Y cells, incubated these membranes with
diﬀerent plasmalogens and measured β-secretase activity
with a ﬂuorescent β-secretase assay [41, 42]. PC-PL 18:1
andPC-PL 22:6slightlydirectlyreducedβ-secretase activity,
whereas PC-PL 20:4 and PE-PL 22:6 revealed no eﬀect
on β-secretase activity (Figure 3(a)). To analyze a potential
direct eﬀect of plasmalogens on β-secretase activity ex vivo,
wepreparedpuriﬁedmembranesofmousebrainsfordirectly
measuring β-secretase activity. PC-PL 18:1 as well as PC-
PL 20:4 showed slightly, however, not signiﬁcant decreased
β-secretase activity in puriﬁed membranes of mouse brains
(Figure 3(b)). To validate these results, we incubated living
SH-SY5Y cells in culture with PC-PL 18:1 and PC-PL
20:4, puriﬁed the membranes of the incubated cells and
determined β-secretase activity. The β-secretase activity was
not signiﬁcantly aﬀected in presence of plasmalogen PC-
PL 18:1, whereas PC-PL 20:4 slightly reduced β-secretase
activity (Figure 3(c)).
3.4. Plasmalogens Reduce Amyloidogenic Processing by Aﬀect-
ing γ-Secretase Activity. As described above, we observed no
or only slightly reduced β-secretase activity in the presence
of plasmalogens, indicating that the initial step in the gener-
ation of Aβ is not or only slightly aﬀected by plasmalogens.
To evaluate a potential eﬀect of plasmalogens on the ﬁnal
step in the generation of Aβ peptides, we analyzed the
eﬀect of plasmalogens on γ-secretase activity. Similar to the
experiment for the determination of β-secretase activity, we
ﬁrst incubated puriﬁed membranes of SH-SY5Y cells with
diﬀerent plasmalogens, PC-PL 18:1, PC-PL 20:4, PC-PL
22:6, and PE-PL 22:6, and directly measured γ-secretase
activity. All analyzed plasmalogens PC-PL 18:1, PC-PL
20:4, PC-PL 22:6, and PE-PL 22:6 signiﬁcantly reduced
γ-secretase activity (Figure 4(a)). The strongest eﬀect was
observed for PC-PL 22:6, which reduced γ-secretase activity
to 60%. In agreement with these ﬁndings, PC-PL 18:1 and
PC-PL 20:4 also signiﬁcantly reduced γ-secretase activity
of ex vivo puriﬁed membranes from mouse brains to 80%
(Figure 4(b)). Similar results were obtained when SH-SY5Y
cellswereculturedinpresenceofPC-PL18:1orPC-PL20:4
(Figure 4(c)).
3.5. Inﬂuence of Plasmalogens on α-Secretase Activity. In con-
trast to β-secretase cleavage of APP which generates the N-
terminus of Aβ, APP shedding by α-secretase prevents the
formation of toxic Aβ peptides, because α-secretase cleaves
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Figure 2: Proteinlevel ofthe secretases involved inAPP processing.
(a) SH-SY5Y cells were incubated with PC-PL 18:1 and the
corresponding phospholipid PC 18:1. Cell lysates were prepared,
subjected to gel electrophoresis and Western blot (WB) analysis.
Protein level of ADAM17, PS1, and BACE1 were detected with
antibodies ab39162, sc-7860 and B0806, respectively. (b) Eﬀect
of PC-PL 20:4 on protein level of ADAM17, PS1, and BACE1
compared to the corresponding phospholipid PC 20:4. Detection
was performed as described for (a). All quantiﬁed data represent an
average of at least three independent experiments. Error bars rep-
resent standard deviation of the mean.Asterisks show the statistical
signiﬁcance (∗P ≤ 0.05; ∗∗P ≤ 0.01 and ∗∗∗P ≤ 0.001, n.s. = not
signiﬁcant).(a,b)RepresentativeWBsofproteindeterminationand
representative agarose gels of RT-PCR analyis are shown.
APP within the Aβ domain [32, 33, 43]. In order to evaluate
whether plasmalogens also aﬀect nonamyloidogenic pro-
cessing of APP, we directly measured α-secretase activity in
puriﬁed membranes of SH-SY5Y cells and mouse brains.
Plasmalogens PC-PL 18:1 and PC-PL 22:6showed no eﬀect
onα-secretase activity,whereas PC-PL 20:4and PE-PL 22:6
signiﬁcantly increased α-secretase activity by 10% to 20%
(Figure 5(a)) in puriﬁed membranes of SH-SY5Ycells. How-
ever,α-secretase activitywasnotsigniﬁcantlyelevatedforany8 The Scientiﬁc World Journal
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Figure 3: Eﬀect of PC-PL 18:1, PC-PL 20:4, PC-PL 22:6 and PE-PL 22:6 on β-secretase activity. (a) Inﬂuence on β-secretase activity
in puriﬁed membranes of human SH-SY5Y cells. Puriﬁed membranes of SH-SY5Y cells were prepared, incubated with PC-PL 18:1, 20:4,
22:6, or PE-PL 22:6 and the corresponding phospholipids (100μM), and β-secretase activity was determined by a ﬂuorometric assay. A
representative kinetic is shown for PC-PL 18:1 and PC 18:1. (b) Inﬂuence on β-secretase activity ex vivo in puriﬁed membranes of mouse
brains. Puriﬁed membranes of mouse brains were incubated with PC-PL 18:1 and PC-PL 20:4 and the corresponding phospholipids PC
18:1 andPC 20:4 (100μM). Arepresentative kinetic isshownforPC-PL18:1 andPC18:1. (c)Living SH-SY5Ycells were incubated in cell
culture with PC-PL 18:1 and PC-PL 20:4 and the corresponding phospholipids in a ﬁnal concentration of 100μM for 24 hours. After the
incubation, puriﬁed membranes were prepared and analyzed in the β-secretase assay. A representative kinetic is shown for PC-PL 18:1 and
PC 18:1. (a, b, c) All quantiﬁed data represent an average of at least three independent experiments. Illustration and statistical signiﬁcance
are as described for Figure 2.The Scientiﬁc World Journal 9
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Figure 4: Determination of γ-secretase activity in the presence of PC-PL 18:1, PC-PL 20:4, PC-PL 22:6, and PE-PL 22:6. (a) Inﬂuence
on γ-secretase activity in puriﬁed membranes of human SH-SY5Y cells. Puriﬁed membranes of SH-SY5Y cell were incubated with PC-PL
18:1,20:4,22:6,orPE-PL 22:6 andthecorresponding phospholipids(100μM),andγ-secretase activity was determined by a ﬂuorometric
assay.(b) Inﬂuence onγ-secretase activity ex vivo in puriﬁed membranes of mousebrains.Puriﬁed mousebrain membranes were incubated
with PC-PL 18:1 and PC-PL 20:4 and the corresponding phospholipids (100μM), and γ-secretase activity was determined. (c) Cultured
SH-SY5Y cells were incubated with PC-PL 18:1 and PC-PL 20:4 and the corresponding phospholipids PC 18:1 and PC 20:4 for 24 hours
in a ﬁnal concentration of 100μM. Membranes of incubated SH-SY5Y cells were prepared and γ-secretase activity was determined with a
ﬂuorometric assay. (a, b, c) Representative kinetics are shown for PC-PL 18:1 and PC 18:1. All quantiﬁed data represent an average of at
least three independent experiments. Illustration and statistical signiﬁcance are as described for Figure 2.10 The Scientiﬁc World Journal
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Figure 5: Eﬀect of PC-PL 18:1, PC-PL 20:4, PC-PL 22:6, and PE-PL 22:6 on α-secretase activity. PC-PL 18:1, PC-PL 20:4, PC-PL 22:6
and PE-PL 22:6 and the corresponding phospholipids (100μM) were incubated on puriﬁed membranes of (a) human SH-SY5Y cells and
(b) mouse brains, and α-secretase activity was determined as described in materials and methods. (a, b) Representative kinetics were shown
for PC-PL 18:1 and PC 18:1. All quantiﬁed data represent an average of at least three independent experiments. Illustration and statistical
signiﬁcance as described for Figure 2.
oftheanalyzed plasmalogens, PC-PL 18:1,PC-PL20:4,PC-
PL22:6,andPE-PL22:6when weusedpuriﬁedmembranes
of mouse brains instead of SH-SY5Y membranes.
3.6. Inﬂuence of PC-PL on γ-Secretase Activity in Human
AD Brains. Above ﬁndings indicate that PC-PL reduce amy-
loidogenicprocessingofAPPbyaﬀectingγ-secretase activity.
The signiﬁcantly reduced levels of PC-PL in the analyzed
AD postmortem brains might therefore in return increase γ-
secretase activity, leading to the massive generation of Aβ
peptides,oneofthecharacteristichallmarksforAD.Toreveal
whether an increase in plasmalogens is in principle able to
decrease γ-secretase in human AD brains we prepared puri-
ﬁed membranes of six AD postmortem brains and incubated
these membranes with PC-PL 18:1 and PC-PL 20:4 and
the corresponding PC phospholipids. Asdescribed above,we
found that PC-PL 18:1 is one of the species which is mostly
changed in AD brains and was therefore selected for the
incubation experiments. Indeed supplementation with PC-
PL 18:1 reduced γ-secretase activity in ﬁve out of six AD
brains (Figures 6(a) and 6(b)). A similar result was obtained
by incubation with PC-PL 20:4. Interestingly, the same
AD brain, which showed instead of decreased, increased γ-
secretase activity for PC-PL 18:1 also showed increasedThe Scientiﬁc World Journal 11
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Figure6:Eﬀect ofPC-PL18:1andPC-PL20:4onγ-secretaseactivityinpuriﬁed membranesofhumanADpostmortembrains.Membranes
ofsixhumanAD postmortembrain sampleswere puriﬁed andincubated with (a)PC-PL 18:1andthe correspondingphospholipidPC18:1
or (b) PC-PL 20:4 and PC 20:4 as control. PC-PLs and corresponding phospholipids were incubated in a ﬁnal concentration of 100μM
and γ-secretase activity was determined with a ﬂuorometric assay. (a, b) Representative kinetics were shown. Illustration and statistical
signiﬁcance are as described for Figure 2.
γ-secretase activity for PC-PL 20:4 as well (AD brain 5,
Figure 6).However,intotal,PC-PL 18:1reducedγ-secretase
activity to 80%, statistical analysis revealed a P value of
0.0508 (Figure 6(a)). For PC-PL 20:4, the mean reduction
in γ-secretase activity was in a similar range with a P value
of0.268, when the results ofall six ADbrains were combined
(Figure 6(b)).
4.Discussion
Plasmalogens are a subclass of glycerophospholipids char-
acterized by the presence of an enol ether substituent at
the sn-1 position of the glycerol backbone [1]. Beside phos-
phoethanolamine-plasmalogens( P E - P L ) ,r e p o r t e dt ob et h e
major plasmalogens in the brain, a further plasmalogen
species,phosphatidylcholine-plasmalogens (PC-PL)occurin
brain [3, 44]. Plasmalogens are common constituents of
cellular membranes, most abundant in brain and heart, with
important functions like signal transduction, ion transport,
membrane fusion, cell-cell communication, and cholesterol
dynamics (reviewed in: [3]). Alterations in the lipid com-
position ofcellularmembranesaﬀect membrane ﬂuidityand
a number of cellular functions [45]a n do c c u ri ns e v e r a l
diseases, including AD [15, 17, 46–48], Parkinson’s Disease12 The Scientiﬁc World Journal
[49], Creutzfeldt-Jakob disease [50, 51], Gaucher disease
[52], and Fabry disease [53, 54]. Recent studies have shown
thatseverallipidsinﬂuencetheproteolyticprocessingofAPP.
Cholesterol and GM1 are reported to increase the generation
of Aβ [55–57], whereas docosahexaenoic acid and sphin-
gomyelin decrease amyloidogenic processing of APP [42,
58]. Beside their inﬂuence on the generation of Aβ, altered
lipid composition might also aﬀect the recently identiﬁed
physiological function of APP. Beside the neuroprotective
and memory enhancing eﬀect ofα-secreted APP [59–61], we
and others could show that Aβ and the intracellular domain
of APP (AICD), which is beside Aβ released by γ-secretase
cleavage of β-CTF, regulate lipid homeostasis and gene tran-
scription [39, 58, 62, 63]. AICD has been reported to aﬀect
gene transcription of several proteins, including APP, BACE,
GSK3β [62], serine-palmitoyl-CoA transferase [63], and
alkyl-dihydroxyacetonephosphate-synthase (AGPS) [39], a
rate limiting enzyme in plasmalogen synthesis. Although
plasmalogen levels are altered in AD brain samples and are
major constituents of neuronal membranes, so far, it is not
known whether plasmalogens aﬀect the proteolytic process-
ing of APP. Our studies on the proteolytic processing of
APP revealed that plasmalogens decrease the amyloidogenic
processing of APP. The detailed analysis of the secretases
involved in Aβ generation, β-a n dγ-secretase, revealed
that plasmalogens decrease amyloidogenic processing by
reducing γ-secretase activity, whereas no or only a very
slight reduction in the enzymatic activity of β-secretase was
determined. All PC-PL and PE-PL species analyzed showed
a highly signiﬁcant decrease in γ-secretase activity to 60%–
85% compared to the corresponding phospholipid lacking
theenolether. Allplasmalogens independentofthefatty acid
showed adecreasein γ-secretase activityfurtheremphasizing
thatthe observedeﬀectis dueto theenol etherand notto the
fatty acid. Analyzed protein levelsof PS1 and BACE1 in pres-
ence of PC-PL 18:1 and PC-PL 20:4 and RT-PCR analysis
of PC-PL 18:1 or PC-PL 20:4 incubated cells showed that
plasmalogens do not aﬀect gene expression of the secretases
involved in amyloidogenic processing of APP. This result
is in line with our ﬁnding that PC-PL 18:1 and PC-PL
20:4 incubated cultured SH-SY5Y cells showed a similar
reduction in γ-secretase activity like puriﬁed membranes
of SH-SY5Y cells incubated with PC-PL 18:1 or PC-PL
20:4, further strengthening our ﬁnding that plasmalogens
directly reduce the enzymatic activity of γ-secretase and that
it is unlikely that indirect eﬀects of plasmalogens might
inﬂuence γ-secretase activity. The α-secretase activity, which
prevents the formation of Aβ peptides, was in contrast to
γ-secretase diversely aﬀected by plasmalogens. Whereas PC-
PL 18:1 and PC-PL 22:6 showed no signiﬁcant diﬀerences
in α-secretase activity compared to PC 18:1 and PC 22:6,
respectively, PC-PL 20:4 and PE-PL 22:6 signiﬁcantly
increased directly α-secretase activity compared to the
corresponding phospholipids suggesting that the fatty acids
or the phospholipid headgroups are at least able to modulate
the eﬀect of the enol ether on α-secretase activity. However,
this increase in α-secretase activity was only obtained when
puriﬁed membranes of SH-SY5Y cells were used for the α-
secretase assay, whereas on puriﬁed membranes of mouse
brains all plasmalogens showed no signiﬁcant changes in
α-secretase activity. Many matrix metalloproteases (MMPs)
are known to contribute to the α-secretase activity initiating
the nonamyloidogenic pathway [32–34, 64]. These MMPs
are diﬀerentially expressed in diﬀerent cell lines or tissues
[65–67]. The diﬀerent eﬀect for PC-PL 20:4 and PE-PL
22:6 might therefore be a result of diﬀerent α-secretase
composition in SH-SY5Y cells and mouse brains. Similar
to the eﬀect on the protein level and RNA level of BACE1
and the γ-secretase components, PC-PL 18:1 and PC-PL
20:4 revealed no changes in gene transcription of ADAM17.
Because of the cell-type-speciﬁc eﬀect of some plasmalogen
species, we cannot exclude that plasmalogens inﬂuence
some other MMPs, which contribute to α-secretase activity.
However these eﬀects cannot be observed for all tested
plasmalogens pointing out that in respect to α-secretase the
enol ether has only a minor or modulating eﬀect.
To test if our ﬁndings are relevant in AD, we analyzed
whether AD postmortem brains show altered levels of PC-PL
and PE-PL. For PE-PL several studies have revealed that PE-
PL level are reduced in AD brain [15, 17, 23, 68]. However,
one study reported no diﬀerences or even a slight increase
in PE-PL level in AD [25]. By analyzing 37 AD postmortem
brain samples compared to 21 control brains not aﬀected
by AD, we found PE-PL level to be reduced in AD brains;
however, statistical analysis of the single PE-PL species
revealed no signiﬁcance. These ﬁndings are in line with the
reducedPE-PLlevelreported byGinsberg etal. [15]an dH an
et al. [24, 68] and our recent study that revealed also reduced
PC-PL level in AD postmortem brain [40]. Interestingly,
PC-PL level were signiﬁcantly decreased in AD postmortem
brain, indicating that PC-PL might play an important role in
the development of AD, although PC-PL are less abundant
in neuronal membranes compared to PE-PL [44]. The
importance of PC-PL is further substantiated by the results
obtained for γ-secretase activities. As PC-PL level showed
the most prominent reduction in AD brains and AD brains
show increased Aβ generation and accumulation, we tested
whetherincubationofPC-PL18:1andPC-PL20:4onpuri-
ﬁed membranes of human AD postmortem brains might also
reduce γ-secretase activity. Indeed, supplementation with
PC-PL 18:1 or PC-PL 20:4 on AD brain samples reduced
γ-secretase activity in ﬁve out of six analyzed AD brains,
further strengthening the importance of PC-PL in APP
processing and probably the development of AD. Incubating
plasmalogens ex vivo on human postmortem material has
its clear limitations; further studies are required to clarify
whether an increase in plasmalogen levels are a suitable
target, which might have a positive impact in AD.
However, the importance of plasmalogens on the patho-
genesis of AD is further substantiated by our recent ﬁnding
that AGPS, a rate-limiting enzyme in plasmalogen synthesis,
is regulated by APP processing [39]. Increased Aβ levels as
observedinADleadtoperoxisomaldysfunction andreduced
AGPS protein stability, resulting in reduced AGPS protein
level and reduced plasmalogen de novo synthesis [39].
Furthermore, Aβ peptides have been shown to increase the
formationofreactiveoxidativespecies[69–74],alsoreducing
plasmalogen levels, because plasmalogens are susceptibleThe Scientiﬁc World Journal 13
to oxidative stress and function as antioxidants. Reduced
plasmalogen levels in AD might also be a result of increased
phospholipase A2 activity. Sanchez-Mejia et al. recently
reported that Aβ stimulates phospholipase A2 [75, 76],
responsible for the degradation of plasmalogens. Increased
levels of Aβ peptides therefore, decrease plasmalogen levels
by reducing AGPS protein stability, increasing oxidative
stress and activation of phospholipase A2. Therefore, in AD,
a vicious cycle between APP processing and plasmalogen
level occurs. Aβ peptides reduce the plasmalogen level and
reduced plasmalogen level directly increase γ-secretase activ-
ity leading to an even stronger production of Aβ peptides.
In summary, our ﬁndings indicate that plasmalogens might
play a crucial role in the development of AD and that a
delicate balance in lipid composition of cellular membranes
is important for neuronal function.
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